Verwendung von Mimerian-Inhibierenden Substanz (mis)-Proteinen zur Empfängnisverhütung und zur Eierstockreservation
Anmelder: The General Hospital Corporation 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4752229
- Anmeldetag
- 11. Dezember 2014
- Veröffentlichung
- 3. Juni 2026
- Rechtsraum
- EP
- IPC
- C12N15/861
Abstract
One aspect of the invention provides a method of contraception by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). The MIS can be produced endogenously in the subject by a vector, where the vector comprises a polynucletide encoding a recombinant MIS protein. In some embodiments, the contraception is permanent and only requires administration of the composition once. Another aspect of the invention relates to a method of preserving an ovarian reserve, the method comprising administering to a female subject a composition comprising MIS or an inducible vector that comprises a polynucleotide encoding a recombinant MIS protein.
Anmelder
- Firma
- The General Hospital Corporation
- Land
- 🇺🇸 USA
Rechtsträger des Massachusetts General Hospital, eines Harvard-affiliierten Lehrkrankenhauses in Boston (USA), mit umfangreicher medizinischer Forschung.
1.896 Patente in unserer Datenbank